Perimeter Medical Imaging AI (TSE:PINK)
:PINK
Want to see TSE:PINK full AI Analyst Report?
Top Page
Perimeter Medical Imaging AI
(PINK)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.33
▼(-22.62% Downside)
Action:ReiteratedDate:04/15/26
The score is held back primarily by weak financial performance—large net losses and ongoing cash burn despite improving revenue and positive gross profit. Technicals are moderately supportive with price above key moving averages, but valuation remains constrained by the lack of profitability and no dividend yield data.
Positive Factors
Early commercial traction & positive gross profit
Sustained revenue growth with a positive gross profit suggests the core imaging system and consumables have product-market fit. Durable gross margins create a path to leverage operating leverage as placements and per-procedure use scale, supporting long-term unit economics.
Negative Factors
Substantial and persistent cash burn
Material negative operating and free cash flow reflects ongoing investment in commercialization and R&D. Persisting burn creates dependency on external financing, raising dilution risk and constraining the company’s ability to self-fund growth over the next several quarters without capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Early commercial traction & positive gross profit
Sustained revenue growth with a positive gross profit suggests the core imaging system and consumables have product-market fit. Durable gross margins create a path to leverage operating leverage as placements and per-procedure use scale, supporting long-term unit economics.
Read all positive factors
Perimeter Medical Imaging AI (PINK) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$40.99M
Dividend YieldN/A
Average Volume (3M)55.39K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth176.72%
EPS Growth30.90%
CountryCA
Employees65
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.05
Shares Outstanding126,112,560
10 Day Avg. Volume68,307
30 Day Avg. Volume55,392
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)7.00
Price to Sales (P/S)12.31
P/FCF Ratio-3.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.98Price Target Upside370.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.08
Revenue Forecast (FY)C$6.86M
Perimeter Medical Imaging AI Business Overview & Revenue Model
Company Description
Perimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The co...
How the Company Makes Money
Perimeter Medical Imaging AI primarily makes money by selling and deploying its intraoperative imaging platform to healthcare providers, generating revenue from system placements and ongoing use. Key revenue streams include: (1) capital equipment ...
Perimeter Medical Imaging AI Earnings Call Summary
Earnings Call Date:Aug 26, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Jun 02, 2026
Earnings Call Sentiment Neutral
The earnings call reflects significant positive developments, such as strong revenue growth, positive trial results, and increased product utilization. However, challenges remain with an increased net loss, limited cash reserves, and constraints due to a small commercial team. While the highlights are impressive, the lowlights present notable hurdles that need addressing.Positive Updates
Significant Revenue Growth
The company recorded revenue of $506,000 for Q2 2025, representing a 105% increase over Q2 2024. Additionally, revenue for the first six months of 2025 was 25% higher than the total for all of 2024.
Negative Updates
Net Loss Increase
Second quarter 2025 net loss was $3.9 million compared to $3.2 million in the same period in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
The company recorded revenue of $506,000 for Q2 2025, representing a 105% increase over Q2 2024. Additionally, revenue for the first six months of 2025 was 25% higher than the total for all of 2024.
Read all positive updates
Company Guidance
During the Perimeter Medical Second Quarter 2025 Conference Call, key financial and operational metrics were highlighted. The company recorded $506,000 in revenue for the quarter ending June 30, 2025, marking a 105% increase from Q2 2024. The gross margin remained consistent at 70%. Operating expenses decreased by 22% to $4.3 million compared to the same period in 2024. Despite these improvements, Perimeter reported a net loss of $3.9 million. The company had cash and cash equivalents of approximately $1.4 million, excluding $1.6 million from a recent offering and a $745,000 grant receivable. The CEO, Adrian Mendes, emphasized ongoing efforts to commercialize the FDA-cleared S-Series OCT system, with a 25% revenue increase in the first half of 2025 compared to all of 2024. Utilization rates showed significant growth of 93% year-over-year and 35% sequentially. The company is awaiting FDA approval for its next-generation B-Series device, expected by late Q4 2025 or Q1 2026, and is preparing for an aggressive rollout. Cost-saving measures are projected to reduce operating expenses by approximately 30% starting in Q3.Perimeter Medical Imaging AI Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
23
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.34M | 846.19K | 403.53K | 132.77K | 11.34K |
| Gross Profit | 1.03M | 535.11K | 206.42K | 100.63K | 5.04K |
| EBITDA | -12.32M | -12.64M | -18.13M | -11.72M | -15.95M |
| Net Income | -13.14M | -13.39M | -18.94M | -3.59M | -16.76M |
Balance Sheet | |||||
| Total Assets | 6.72M | 14.33M | 27.09M | 34.60M | 9.98M |
| Cash, Cash Equivalents and Short-Term Investments | 2.47M | 6.18M | 18.43M | 28.44M | 5.14M |
| Total Debt | 119.11K | 137.48K | 192.89K | 325.68K | 441.17K |
| Total Liabilities | 2.60M | 3.87M | 7.10M | 8.49M | 2.56M |
| Stockholders Equity | 4.12M | 10.45M | 15.06M | 26.11M | 7.42M |
Cash Flow | |||||
| Free Cash Flow | -9.55M | -16.90M | -15.17M | -13.86M | -16.03M |
| Operating Cash Flow | -9.42M | -14.72M | -14.70M | -11.87M | -13.91M |
| Investing Cash Flow | -130.44K | -1.90M | 206.01K | -1.75M | -1.45M |
| Financing Cash Flow | 5.85M | 8.58M | 234.47K | 40.28M | 10.06M |
Perimeter Medical Imaging AI Technical Analysis
Positive
0.42
Price Trends
0.38
Positive
0.34
Positive
0.29
Positive
Market Momentum
>-0.01
Negative
52.97
Neutral
75.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Positive. The current price of 0.42 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.38, and above the 200-day MA of 0.29, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.97 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PINK.
Perimeter Medical Imaging AI Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | C$40.99M | -5.70 | -258.64% | ― | 176.72% | 30.90% | |
50 Neutral | C$18.77M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
46 Neutral | C$21.47M | -29.60 | -31.12% | ― | 9.71% | -118.02% | |
46 Neutral | C$100.25M | -11.76 | -315.07% | ― | 1.46% | 6.91% |
* General Sector Average
TSE:PINK
Perimeter Medical Imaging AI
0.34
-0.05
-12.99%
TSE:ASG
Aurora Spine
0.28
-0.07
-21.43%
TSE:IME
Imagin Medical
0.02
0.00
0.00%
TSE:TLT
Theralase Technologies
0.33
0.15
80.56%
TSE:VPT
VentriPoint Diagnostics
0.12
-0.02
-11.11%
Perimeter Medical Imaging AI Corporate Events
Business Operations and StrategyProduct-Related Announcements
Perimeter Medical Imaging AI to Present at 2026 Bloom Burton Healthcare Investor Conference
Positive
Apr 14, 2026
Perimeter Medical Imaging AI announced that its management will present a business update at the 2026 Bloom Burton Co. Healthcare Investor Conference in Toronto on April 21, 2026, with the session also streamed live and archived on its website. T...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Perimeter Posts Record 2025 Revenue and Wins FDA Approval for AI Breast Imaging Device
Positive
Apr 1, 2026
Perimeter reported preliminary unaudited 2025 results showing record revenue of $711,000 in Q4, up 143% year-over-year, and $2.3 million for the full year, a 172% increase, driven by growing adoption of its S-Series OCT system. The company expande...
Business Operations and StrategyFinancial Disclosures
Perimeter Sets Date for 2025 Results and Cuts Dilution With Major Warrant Cancellation
Positive
Mar 24, 2026
Perimeter Medical Imaging AI said it will release its fourth quarter and full-year 2025 financial and operating results after markets close on March 31, 2026, followed by a webcast and conference call with management to discuss the numbers and pro...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Perimeter Wins FDA Nod for First AI Imaging Device in Breast Cancer Surgery
Positive
Mar 3, 2026
Perimeter Medical Imaging AI has received U.S. FDA premarket approval for Claire, the first AI-enabled imaging device cleared in the United States for intraoperative breast cancer margin assessment. Combining proprietary AI with wide-field OCT, Cl...
Business Operations and Strategy
Perimeter Medical Imaging AI Reprices Employee Stock Options to Boost Incentives
Positive
Feb 17, 2026
Perimeter Medical Imaging AI plans to cancel up to 2,175,619 previously issued employee and consultant stock options, which carry exercise prices between C$0.38 and C$2.85, and replace them with an equal number of options exercisable at C$0.30. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.